Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
A simple blood test detects over 30 types of cancers
Subscribe To Our Newsletter & Stay Updated
